Valuation: Galapagos NV

Market Cap 167.42Cr 195.17Cr 195.17Cr 156.33Cr 143.43Cr 269.72Cr 19TCr 274.16Cr 1.84TCr 722.34Cr 9.36TCr 732.84Cr 716.9Cr 31TCr P/E 2026 *
-12.6x
P/E 2027 * -6.36x
Enterprise Value -76Cr -88Cr -88Cr -71Cr -65Cr -121.84Cr -8.43TCr -123.84Cr -833.26Cr -326.29Cr -4.23TCr -331.03Cr -323.83Cr -14TCr EV / Sales 2026 *
-7.97x
EV / Sales 2027 * -6.31x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 12/05/2025
Director of Finance/CFO 41 07/07/2025
Chief Operating Officer - 01/06/2026
Director TitleAgeSince
Director/Board Member 63 22/10/2019
Director/Board Member 49 07/10/2024
Director/Board Member 53 12/05/2025
Change 5-day change 1-year change 3-year change Capi.($)
+2.37%+0.66%+4.21%+22.74% 4.86TCr
-0.62%+4.58%+487.47%+618.65% 4.63TCr
+2.09%+4.96%+20.59%+92.16% 4.2TCr
+3.85%+3.13%+29.60%+16.29% 3.95TCr
-0.72%-7.79%+17.87%+47.98% 3.17TCr
+3.04%+1.89%+31.62%+147.28% 1.65TCr
+4.33%+1.63% - - 1.63TCr
+1.44%+1.09%+4.93%+31.00% 1.4TCr
+3.87%+1.98%+82.99%+44.34% 1.33TCr
Average +2.00%-0.60%+84.91%+127.55% 2.98TCr
Weighted average by Cap. +1.77%-0.05%+107.44%+155.71%

Financials

2026 *2027 *
Net sales 9.49Cr 11Cr 11Cr 8.86Cr 8.13Cr 15Cr 1.06TCr 16Cr 104.53Cr 41Cr 530.15Cr 42Cr 41Cr 1.75TCr 9.33Cr 11Cr 11Cr 8.71Cr 7.99Cr 15Cr 1.04TCr 15Cr 102.79Cr 40Cr 521.35Cr 41Cr 40Cr 1.72TCr
Net income -4.07Cr -4.74Cr -4.74Cr -3.8Cr -3.49Cr -6.56Cr -453.46Cr -6.66Cr -45Cr -18Cr -227.42Cr -18Cr -17Cr -751.94Cr -21Cr -25Cr -25Cr -20Cr -18Cr -34Cr -2.37TCr -35Cr -234.35Cr -92Cr -1.19TCr -93Cr -91Cr -3.93TCr
Net Debt -243.05Cr -283.34Cr -283.34Cr -226.95Cr -208.22Cr -391.56Cr -27TCr -398Cr -2.68TCr -1.05TCr -14TCr -1.06TCr -1.04TCr -45TCr -226.33Cr -263.85Cr -263.85Cr -211.34Cr -193.9Cr -364.63Cr -25TCr -370.63Cr -2.49TCr -976.52Cr -13TCr -990.72Cr -969.16Cr -42TCr
Logo Galapagos NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B